History of Vaccines Blog

Phase 3 Trial of Recombinant Shingles Vaccine Shows Promise in Older Adults

July 15, 2015

Shingles on face and in mouth, 1835The herpes zoster vaccine commercially available in the United States (Zostavax, Merck, generic zoster vaccine live) is 51% effective at preventing shingles in adults ages 60 and older, but it is less effective for older adults. For those over age 70, it is only 38% effective at preventing disease.